Page last updated: 2024-09-05

senicapoc and Pain

senicapoc has been researched along with Pain in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ataga, KI; Ballas, SK; Bigelow, C; Galacteros, F; Hull, JH; James, LS; Kutlar, A; Reid, M; Smith, WR; Stocker, JW; Yasin, Z1
Castro, OL; Gladwin, MT; Gordeuk, VR; Steinberg, MH1

Trials

1 trial(s) available for senicapoc and Pain

ArticleYear
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapo
    British journal of haematology, 2011, Volume: 153, Issue:1

    Topics: Acetamides; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Drug Administration Schedule; Erythrocyte Aging; Female; Hematocrit; Hemolysis; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Middle Aged; Pain; Treatment Outcome; Trityl Compounds; Young Adult

2011

Other Studies

1 other study(ies) available for senicapoc and Pain

ArticleYear
Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.
    British journal of haematology, 2011, Volume: 155, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Hemoglobin, Sickle; Humans; Pain; Phenotype; Randomized Controlled Trials as Topic; Trityl Compounds

2011